- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- November 2023
- 47 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- March 2019
- 164 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- March 2019
- 42 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- April 2023
- 88 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2023
- 213 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- August 2022
United States
From €1844EUR$1,940USD£1,549GBP
- Report
- August 2022
Global
From €1131EUR$1,190USD£950GBP
- Drug Pipelines
- January 2023
- 35 Pages
Global
From €9502EUR$9,995USD£7,982GBP
- Report
- August 2023
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 93 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- December 2022
- 1182 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- March 2023
- 411 Pages
Global
From €3394EUR$3,570USD£2,851GBP

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse.
The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more